<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of atherosclerotic cardiovascular risk factors in females</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of atherosclerotic cardiovascular risk factors in females</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of atherosclerotic cardiovascular risk factors in females</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pamela S Douglas, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Athena Poppas, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stacie L Daugherty, MD, MSPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joann G Elmore, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara Swenson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Clinicians and patients may have gaps in their awareness of, recognition of, and preparedness to manage atherosclerotic cardiovascular disease (ASCVD) risk in females [<a href="#rid1">1-3</a>]. This topic will present an overview of ASCVD risk factors in females.</p><p>Related issues are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>ASCVD risk assessment in adults. These topics include discussion of sex-specific ASCVD risk assessment. (See  <a class="medical medical_review" href="/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a> and  <a class="medical medical_review" href="/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"</a> and  <a class="medical medical_review" href="/d/html/114029.html" rel="external">"Cardiovascular disease risk assessment for primary prevention: Risk calculators"</a> and  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of ASCVD. (See  <a class="medical medical_review" href="/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The management of ASCVD, including management of coronary heart disease in women. (See  <a class="medical medical_review" href="/d/html/1520.html" rel="external">"Management of coronary heart disease in women"</a> and  <a class="medical medical_review" href="/d/html/1120.html" rel="external">"Overview of secondary prevention of ischemic stroke"</a> and  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS AND EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Atherosclerotic cardiovascular disease (ASCVD) includes four major areas:</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary heart disease (CHD) clinically manifested by myocardial infarction, angina pectoris, and coronary death. CHD is a common cause of heart failure. (See  <a class="medical medical_review" href="/d/html/3479.html" rel="external">"Epidemiology of heart failure"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cerebrovascular disease clinically manifested by stroke and transient ischemic attack.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral artery disease clinically manifested by intermittent claudication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aortic atherosclerosis and thoracic or abdominal aortic aneurysm.</p><p></p><p>The presence of vascular disease in one of these territories significantly increases the likelihood of disease in other vascular distributions. (See  <a class="medical medical_review" href="/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease", section on 'Noncoronary atherosclerotic disease'</a>.)</p><p>ASCVD is the leading cause of death worldwide in females and males [<a href="#rid4">4</a>], accounting for 4.8 and 4.9 million deaths respectively in 2017 [<a href="#rid5">5</a>]. The CVD burden for females and males in the United States are also similar, causing 21.8 and 24.2 percent of deaths, respectively [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H2740351373"><span class="h1">IMPORTANCE OF TRADITIONAL RISK FACTORS</span><span class="headingEndMark"> — </span>The general approach to atherosclerotic cardiovascular disease (ASCVD) risk assessment and management in females is similar to that in males, as traditional risk factors are relevant for all adults [<a href="#rid4">4</a>]. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p>Additional ASCVD risk markers which are either specific to or more common in females are discussed below. Some of these conditions (certain autoimmune disorders; history of premature menopause; and history of pregnancy-associated conditions associated with ASCVD risk, such as preeclampsia) are included in the American College of Cardiology/American Heart Association (ACC/AHA) list of risk-enhancing factors for clinician-patient risk discussion  (<a class="graphic graphic_table graphicRef131708" href="/d/graphic/131708.html" rel="external">table 1</a>) [<a href="#rid7">7</a>]. These risk factors are not included in standard risk calculators as their value in enhancing ASCVD risk assessment and modifying management has not been established. Some of these risk factors may predict increased risk of developing traditional risk factors such as hypertension and diabetes mellitus, as discussed below. (See <a class="local">'Pregnancy-associated risk markers'</a> below and <a class="local">'Other conditions associated with cardiovascular disease risk'</a> below.)</p><p class="headingAnchor" id="H5575024"><span class="h1">PREGNANCY-ASSOCIATED RISK MARKERS</span><span class="headingEndMark"> — </span>A number of adverse pregnancy outcomes (APOs) are associated with increased subsequent cardiovascular risk [<a href="#rid8">8,9</a>]. Thus, screening for and managing cardiovascular risk factors is an important component of care for patients who have experienced APOs. (See  <a class="medical medical_review" href="/d/html/6805.html" rel="external">"Gestational hypertension", section on 'Maternal prognosis'</a> and  <a class="medical medical_review" href="/d/html/6790.html" rel="external">"Gestational diabetes mellitus: Glucose management and maternal prognosis", section on 'Follow-up'</a> and  <a class="medical medical_review" href="/d/html/97819.html" rel="external">"Overview of preventive care in adults", section on 'Cardiovascular disease prevention'</a>.)</p><p>The value of including APOs in atherosclerotic cardiovascular disease (ASCVD) risk classification has not been established. Studies examining the predictive role of APOs suggest that they may not materially enhance ASCVD risk assessment after accounting for established cardiovascular risk factors [<a href="#rid8">8,10</a>].</p><p>Lactation is associated with reduced ASCVD risk. (See <a class="local">'Protective effect of lactation'</a> below.)</p><p class="headingAnchor" id="H2033219347"><span class="h2">Hypertensive disorder of pregnancy</span><span class="headingEndMark"> — </span>Hypertensive disorder of pregnancy (HDP) includes preeclampsia, gestational hypertension, as well as chronic hypertension occurring during pregnancy. HDP is associated with increased risk of developing chronic hypertension as well as increased risk of ASCVD. It has not been established whether HDP is an independent predictor or ASCVD risk beyond its association with chronic hypertension and other traditional risk factors.</p><p>The risk of developing chronic hypertension and ASCVD in individuals with preeclampsia or gestational hypertension is discussed further separately. (See  <a class="medical medical_review" href="/d/html/6805.html" rel="external">"Gestational hypertension", section on 'Maternal prognosis'</a> and  <a class="medical medical_review" href="/d/html/139247.html" rel="external">"Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Long-term maternal risks of pregnancy-associated hypertension'</a>.)</p><p class="headingAnchor" id="H385618674"><span class="h2">Gestational diabetes</span><span class="headingEndMark"> — </span>Gestational diabetes is associated with an increased risk of developing type 2 diabetes and ASCVD, as discussed separately. (See  <a class="medical medical_review" href="/d/html/6790.html" rel="external">"Gestational diabetes mellitus: Glucose management and maternal prognosis", section on 'Long-term risk'</a>.)</p><p class="headingAnchor" id="H3539684355"><span class="h2">Preterm delivery and delivery of infants with fetal growth restriction</span><span class="headingEndMark"> — </span>Patients who have a spontaneous delivery prior to 37 weeks of gestation have an increased risk of developing ASCVD when compared with those who deliver at term, as discussed separately. (See  <a class="medical medical_review" href="/d/html/6761.html" rel="external">"Spontaneous preterm birth: Overview of risk factors and prognosis", section on 'Long-term maternal consequences'</a>.)</p><p>Adverse cardiovascular prognosis for individuals delivering an infant with fetal growth restriction is discussed separately. (See  <a class="medical medical_review" href="/d/html/139556.html" rel="external">"Fetal growth restriction: Pregnancy management and outcome", section on 'Maternal'</a>.)</p><p class="headingAnchor" id="H4001205904"><span class="h2">Placental abruption</span><span class="headingEndMark"> — </span>Placental abruption is associated with increased subsequent risk of maternal ASCVD, as discussed separately. (See  <a class="medical medical_review" href="/d/html/6803.html" rel="external">"Acute placental abruption: Management and long-term prognosis", section on 'Long-term maternal prognosis'</a>.)</p><p class="headingAnchor" id="H759332739"><span class="h2">Spontaneous pregnancy loss</span><span class="headingEndMark"> — </span>Patients who have experienced spontaneous pregnancy loss (miscarriage, not induced abortion) or stillbirth have elevated subsequent risk of ASCVD, particularly coronary heart disease (CHD) [<a href="#rid11">11-17</a>]. While the cause of this association has not been fully elucidated, it may relate to procoagulant and proinflammatory states that are associated with recurrent miscarriages. Pregnancy loss is also associated with increased risk of developing hypertension and type 2 diabetes [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/5439.html" rel="external">"Pregnancy loss (miscarriage): Terminology, risk factors, and etiology"</a> and  <a class="medical medical_review" href="/d/html/6827.html" rel="external">"Stillbirth: Incidence, risk factors, etiology, and prevention"</a>.)</p><p>In a meta-analysis of 10 studies assessing the risk of ASCVD following a miscarriage (nine reported data on CHD, four reported data on cerebrovascular disease, and three reported data on both), individuals with a prior miscarriage were significantly more likely to develop CHD (odds ratio [OR] 1.45, 95% CI 1.18-1.78) but not cerebrovascular disease (OR 1.11, 95% CI 0.72-1.69) [<a href="#rid15">15</a>]. Among 11,518 adults in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (mean follow-up 10.8 years) who had ever been pregnant, there was a significantly greater risk of myocardial infarction, even after adjusting for traditional risk factors, among those with any history of miscarriage (adjusted hazard ratio [HR] 1.42 compared with no pregnancy loss, 95% CI 1.14-1.78) or stillbirth (adjusted HR 2.65, 95% CI 1.37-5.12) [<a href="#rid11">11</a>]. Individuals with recurrent miscarriages (more than three) were at the highest risk of myocardial infarction (adjusted HR 8.90, 95% CI 3.18-24.90).</p><p>A meta-analysis found that stillbirth was associated with an increased risk of ASCVD-related mortality (HR 2.23, 95% CI 1.90-2.62) [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H1494449976"><span class="h2">Protective effect of lactation</span><span class="headingEndMark"> — </span>As discussed separately, observational data have found that individuals who have lactated have more favorable subsequent cardiovascular and metabolic profiles and reduced cardiovascular risk compared with those who have not lactated. (See  <a class="medical medical_review" href="/d/html/5022.html" rel="external">"Maternal and economic benefits of breastfeeding", section on 'Cardiovascular disease'</a>.)</p><p class="headingAnchor" id="H436032834"><span class="h1">OTHER CONDITIONS ASSOCIATED WITH CARDIOVASCULAR DISEASE RISK</span><span class="headingEndMark"> — </span>A number of other conditions are more common in females and are associated with atherosclerotic cardiovascular disease (ASCVD) risk [<a href="#rid6">6,19</a>].</p><p class="headingAnchor" id="H315697537"><span class="h2">Timing of menarche</span><span class="headingEndMark"> — </span>Either early or late menarche appears to be associated with future ASCVD risk [<a href="#rid20">20-24</a>]. For example, in a cohort of 1.2 million females, premature menarche was associated with an increased risk of developing coronary heart disease (CHD; relative risk [RR] 1.27, 95% CI 1.22-1.31) [<a href="#rid20">20</a>]. Similar findings were reported in a 2014 meta-analysis of six smaller cohorts encompassing fewer than 150,000 women, in which each one-year increase in age at menarche was associated with a 3 percent reduction in total mortality [<a href="#rid21">21</a>]. The WISE trial noted a U-shaped curve of major adverse cardiovascular events among 648 females without surgical menopause with early (≤10 years) or late (≥15 years) menarche, with hazard ratios (HRs) of 4.53 and 2.58 respectively [<a href="#rid24">24</a>]. A similar finding of increased risk but of lesser magnitude was noted in the Million Women Study from the United Kingdom [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H3513314998"><span class="h2">Early menopause</span><span class="headingEndMark"> — </span>Early menopause (occurring at less than age 40), either naturally, surgically, or chemically is associated with an increased risk of ASCVD [<a href="#rid25">25-28</a>]. In a population-based cohort study of 144,260 post-menopausal females, the risk of incident ASCVD (a composite of incident coronary artery disease, heart failure, aortic stenosis, mitral regurgitation, atrial fibrillation, ischemic stroke, peripheral artery disease, and venous thromboembolism) at median seven-year follow-up was higher for women with surgical premature menopause (7.6 percent; HR 1.87) and for those with natural premature menopause (6.0 percent; HR 1.36) than for those without premature menopause (3.9 percent) after adjustment for ASCVD risk factors and use of menopausal hormone therapy (MHT) [<a href="#rid27">27</a>]. Similarly, in 73,814 females in the Nurses’ Health Study, early menopause was associated with a higher multivariable-adjusted risk of ASCVD [<a href="#rid29">29</a>].</p><p>Diagnosis and management of primary ovarian insufficiency is discussed separately. (See  <a class="medical medical_review" href="/d/html/7443.html" rel="external">"Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)"</a> and  <a class="medical medical_review" href="/d/html/7426.html" rel="external">"Management of primary ovarian insufficiency (premature ovarian failure)"</a>.)</p><p class="headingAnchor" id="H2651015753"><span class="h2">Polycystic ovary syndrome</span><span class="headingEndMark"> — </span>Obesity, insulin resistance, impaired glucose tolerance or type 2 diabetes, and dyslipidemia are common in patients with polycystic ovary syndrome (PCOS), and these metabolic disorders may increase the risk of ASCVD; it is unclear if PCOS is an independent risk factor for ASCVD. These issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/7436.html" rel="external">"Clinical manifestations of polycystic ovary syndrome in adults", section on 'Metabolic issues'</a> and  <a class="medical medical_review" href="/d/html/7436.html" rel="external">"Clinical manifestations of polycystic ovary syndrome in adults", section on 'Coronary heart disease'</a>.)</p><p class="headingAnchor" id="H1693493737"><span class="h2">Autoimmune diseases</span><span class="headingEndMark"> — </span>Rheumatoid arthritis, systemic lupus erythematous (SLE), and antiphospholipid antibody syndrome are more common in females and are associated with increased risk of ASCVD [<a href="#rid30">30</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rheumatoid arthritis</strong> – Females are at higher risk for rheumatoid arthritis than males. ASCVD in patients with rheumatoid arthritis is discussed separately. (See  <a class="medical medical_review" href="/d/html/7511.html" rel="external">"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis", section on 'Cardiac disease'</a> and  <a class="medical medical_review" href="/d/html/7511.html" rel="external">"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis", section on 'Noncardiac vascular disease'</a> and  <a class="medical medical_review" href="/d/html/7481.html" rel="external">"Coronary artery disease in rheumatoid arthritis: Pathogenesis, risk factors, clinical manifestations, and diagnostic implications"</a> and  <a class="medical medical_review" href="/d/html/7492.html" rel="external">"Coronary artery disease in rheumatoid arthritis: Implications for prevention and management"</a> and  <a class="medical medical_review" href="/d/html/7511.html" rel="external">"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis"</a>.)</p><p></p><p class="bulletIndent1">In addition, the incidence of heart failure, atrial fibrillation, and peripheral vascular disease in patients with rheumatoid arthritis is higher than in people without rheumatoid arthritis (see  <a class="medical medical_review" href="/d/html/7511.html" rel="external">"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis"</a>). Patients with rheumatoid arthritis may be at increased risk for stroke, although the supporting data are not as conclusive as those reporting an increased risk of coronary artery disease. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/7480.html" rel="external">"Neurologic manifestations of rheumatoid arthritis", section on 'Stroke'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic lupus erythematosus</strong> – Systemic lupus erythematosus (SLE) occurs most often in females, particularly young female adults. Epidemiologic studies have identified elevated ASCVD risk (particularly CHD) among patients with SLE compared with the general population. ASCVD in patients with SLE is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/4680.html" rel="external">"Non-coronary cardiac manifestations of systemic lupus erythematosus in adults"</a> and  <a class="medical medical_review" href="/d/html/4683.html" rel="external">"Coronary artery disease in systemic lupus erythematosus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiphospholipid antibody syndrome </strong>–<strong> </strong>Antiphospholipid antibody syndrome is more prevalent in women and is associated with recurrent venous and arterial thrombosis, valvulopathy, coronary artery disease, and peripheral vascular disease. This condition is discussed separately. (See  <a class="medical medical_review" href="/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome", section on 'Cardiac involvement'</a> and  <a class="medical medical_review" href="/d/html/4678.html" rel="external">"Diagnosis of antiphospholipid syndrome"</a> and  <a class="medical medical_review" href="/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a> and  <a class="medical medical_review" href="/d/html/3073.html" rel="external">"Antiphospholipid syndrome and the kidney"</a>.)</p><p></p><p class="headingAnchor" id="H3101821409"><span class="h2">Breast cancer</span><span class="headingEndMark"> — </span>Observational studies have identified an elevated risk of ASCVD mortality in females with breast cancer. In a systematic review, females with breast cancer had a higher risk of ASCVD death than those in the general population [<a href="#rid31">31</a>]. Mortality was greatest among females who were older at the time of diagnosis (&gt;65 years), Black individuals, and those with a left-sided tumor. One of the included studies found that the elevated ASCVD-mortality risk among breast cancer survivors compared with age-matched controls without breast cancer was evident only seven years after diagnosis [<a href="#rid32">32</a>].</p><p>Several mechanisms have been proposed to explain the association between breast cancer and cardiovascular mortality [<a href="#rid33">33,34</a>]. The “multiple hit” hypothesis suggests that the combined effects of underlying ASCVD risk factors, direct adverse effects of cancer therapy on cardiac function, lifestyle perturbations during and after treatment (eg, decreased physical activity) and concomitant metabolic alterations and decline in cardiovascular reserve result in a higher risk of ASCVD [<a href="#rid35">35</a>]. In addition to these “hits,” ASCVD and breast cancer may share some common biological pathways that may explain disease progression [<a href="#rid33">33,36</a>].</p><p class="headingAnchor" id="H4278036706"><span class="h3">Treatment-related risks</span><span class="headingEndMark"> — </span>Many breast cancer treatments (including radiation therapy, chemotherapy, adjuvant therapies, and endocrine therapies) are associated with early and delayed adverse cardiovascular effects [<a href="#rid34">34</a>]. In addition, patients who experience chemotherapy-induced early menopause have an increased ASCVD risk [<a href="#rid33">33</a>]. (See <a class="local">'Early menopause'</a> above.)</p><p>A comprehensive review of breast cancer therapies, their cardiovascular adverse effects, and recommendations for cardiovascular management is provided elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7062.html" rel="external">"Cardiotoxicity of radiation therapy for breast cancer and other malignancies"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/774.html" rel="external">"Cardiotoxicity of trastuzumab and other HER2-targeted agents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/754.html" rel="external">"Overview of long-term complications of therapy in breast cancer survivors and patterns of relapse", section on 'Cardiovascular morbidity'</a>.)</p><p></p><p class="headingAnchor" id="H262737556"><span class="h3">Other risks</span><span class="headingEndMark"> — </span>Traditional ASCVD risk factors before or at the time of breast cancer diagnosis appear to be the same as those among females without breast cancer [<a href="#rid33">33,37,38</a>]. However, ASCVD and breast cancer share several modifiable risk factors including physical inactivity, obesity or overweight, tobacco use, greater than moderate alcohol intake, and poor diet [<a href="#rid34">34,35,39</a>].</p><p>Decreased physical activity has been observed in individuals diagnosed with and treated for breast cancer [<a href="#rid40">40-42</a>]. For example, in a study of 1696 females with newly diagnosed invasive breast cancer, self-reported physical activity significantly decreased six months post-diagnosis, with the greatest decrease noted in recreational activity (eg, running or jogging, aerobic dance or exercise class, and tennis) [<a href="#rid42">42</a>]. Interventions to improve physical activity in persons with breast cancer are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/14222.html" rel="external">"The roles of diet, physical activity, and body weight in cancer survivors", section on 'Breast cancer'</a>.)</p><p>Weight gain is common following breast cancer treatment due to decreased physical activity and changes in diet [<a href="#rid33">33,43-47</a>]. Several trials have demonstrated that weight loss programs can be successfully implemented and achieve weight loss in breast cancer survivors. (See  <a class="medical medical_review" href="/d/html/14222.html" rel="external">"The roles of diet, physical activity, and body weight in cancer survivors", section on 'Breast cancer'</a>.)</p><p>Systemic inflammation and oxidative stress have been implicated in the development of both atherosclerosis and carcinogenesis [<a href="#rid36">36</a>]. Common intracellular signaling pathways lead to chronic inflammation, oxidative stress, and the activation of cellular processes that underlie both diseases [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H510270372"><span class="h1">HORMONE THERAPY</span></p><p class="headingAnchor" id="H403657201"><span class="h2">Combined estrogen-progestin contraceptives</span><span class="headingEndMark"> — </span>The use of combined estrogen-progestin hormonal contraception (CHC) is associated with increased cardiovascular risk. Contraceptive decision-making based upon consideration of risks and benefits are discussed separately. (See  <a class="medical medical_review" href="/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a> and  <a class="medical medical_review" href="/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Use in patients with medical disorders'</a>.)</p><p class="headingAnchor" id="H2311509767"><span class="h2">Menopausal hormone therapy</span><span class="headingEndMark"> — </span>Cardiovascular risk associated with menopausal hormone therapy (MHT) and patient selection for MHT are discussed separately. (See  <a class="medical medical_review" href="/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks"</a> and  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Contraindications'</a>.)</p><p class="headingAnchor" id="H481364535"><span class="h1">RISKS IN TRANSGENDER INDIVIDUALS</span><span class="headingEndMark"> — </span>Risk factors for ASCVD appear similar in transgender individuals as their cis gender counterparts and include older age, diabetes, and chronic kidney disease [<a href="#rid48">48</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transgender women</strong> – Epidemiological studies suggest that transgender women have a higher risk of myocardial infarction, ischemic strokes, and venous thromboembolic events compared with cisgender (gender identity is the same as sex assigned at birth) women; however, whether this risk is higher than cisgender men is not clear [<a href="#rid49">49-54</a>]. It is not clear whether the increased risk of ASCVD in transgender women is due to gender-affirming hormone therapy or related to their natal sex (ie, male sex at birth).Observational studies suggests that the use of estrogen by transgender women confers an increased risk for ASCVD [<a href="#rid53">53,55,56</a>], perhaps due to a deleterious effect on ASCVD risk factors (eg, lipids and insulin sensitivity) [<a href="#rid49">49,57</a>]. Management of cardiovascular risk factors may decrease the hazards associated with long-term hormone therapy [<a href="#rid55">55</a>].<strong> </strong>(See  <a class="medical medical_review" href="/d/html/82964.html" rel="external">"Primary care of transgender individuals", section on 'Cardiovascular disease'</a> and  <a class="medical medical_review" href="/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transgender men</strong> – There is no clear evidence to suggest that transgender men have an increased risk of ASCVD compared with either cisgender men or cisgender women [<a href="#rid50">50-53,55,56</a>]. Masculinizing hormone therapy alters lipid parameters associated with increased cardiovascular risk, but studies have shown mixed effects on other risk factors, such as blood pressure and insulin sensitivity [<a href="#rid49">49,52,55,56,58,59</a>].</p><p></p><p></p><p class="headingAnchor" id="H3773111167"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119659.html" rel="external">"Society guideline links: Assessment of cardiovascular risk"</a> and  <a class="medical medical_society_guidelines" href="/d/html/111343.html" rel="external">"Society guideline links: Primary prevention of cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H26678620"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/85797.html" rel="external">"Patient education: Coronary artery disease in women (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H34"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The general approach to atherosclerotic cardiovascular disease (ASCVD) risk assessment in females is similar to that in males, as traditional risk factors are relevant for all adults. Some additional risk markers are either specific to or more common in females; the value of these factors in enhancing risk assessment has not been established. Some of these risk factors predict increased risk of traditional risk factors such as hypertension and diabetes. (See <a class="local">'Importance of traditional risk factors'</a> above and  <a class="medical medical_review" href="/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some adverse pregnancy outcomes (APOs) are associated with increased subsequent cardiovascular risk in observational studies. These include hypertensive disorder of pregnancy, gestational diabetes, preterm delivery, placental abruption, and spontaneous pregnancy loss. Thus, screening for and managing cardiovascular risk factors is an important component of care for patients who have experienced adverse pregnancy outcomes. (See <a class="local">'Pregnancy-associated risk markers'</a> above and  <a class="medical medical_review" href="/d/html/6805.html" rel="external">"Gestational hypertension", section on 'Maternal prognosis'</a> and  <a class="medical medical_review" href="/d/html/6790.html" rel="external">"Gestational diabetes mellitus: Glucose management and maternal prognosis", section on 'Follow-up'</a> and  <a class="medical medical_review" href="/d/html/97819.html" rel="external">"Overview of preventive care in adults", section on 'Cardiovascular disease prevention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other conditions or factors associated with increased ASCVD risk include early menarche, late menarche, early menopause, polycystic ovary syndrome (PCOS), and some autoimmune disorders. (See <a class="local">'Other conditions associated with cardiovascular disease risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breast cancer is associated with increased risk of cardiovascular mortality. This association may be caused by the combined effects of underlying ASCVD risk factors, adverse cardiovascular effects of cancer therapy, and adverse metabolic and cardiovascular effects of lifestyle perturbations during and after treatment. (See <a class="local">'Breast cancer'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals who have lactated have reduced cardiovascular risk compared with those who have not lactated. (See <a class="local">'Protective effect of lactation'</a> above and  <a class="medical medical_review" href="/d/html/5022.html" rel="external">"Maternal and economic benefits of breastfeeding", section on 'Cardiovascular disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transgender women have a higher risk of ASCVD compared with cisgender women; however, it is unclear whether the ASCVD risk for transgender women is higher than that for cisgender men. There is no clear evidence to suggest that transgender men have an increased risk of ASCVD compared with either cisgender men or cisgender women. (See <a class="local">'Risks in transgender individuals'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Yu J, Park K, Chandrasekhar J, et al. Feasibility and Utility of a Cardiovascular Risk Screening Tool in Women Undergoing Routine Gynecology Evaluation. J Womens Health (Larchmt) 2020; 29:1150.</a></li><li><a class="nounderline abstract_t">Shaw LJ, Pepine CJ, Xie J, et al. Quality and Equitable Health Care Gaps for Women: Attributions to Sex Differences in Cardiovascular Medicine. J Am Coll Cardiol 2017; 70:373.</a></li><li><a class="nounderline abstract_t">Dhawan S, Bakir M, Jones E, et al. Sex and gender medicine in physician clinical training: results of a large, single-center survey. Biol Sex Differ 2016; 7:37.</a></li><li><a class="nounderline abstract_t">Vogel B, Acevedo M, Appelman Y, et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet 2021; 397:2385.</a></li><li class="breakAll">World Health Organization. World health statistics 2019: Monitoring health for the SDGs. Available at: https://www.who.int/gho/publications/world_health_statistics/2019/en/ (Accessed on August 20, 2020).</li><li><a class="nounderline abstract_t">Maffei S, Guiducci L, Cugusi L, et al. Women-specific predictors of cardiovascular disease risk - new paradigms. Int J Cardiol 2019; 286:190.</a></li><li><a class="nounderline abstract_t">Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 140:e596.</a></li><li><a class="nounderline abstract_t">Parikh NI, Gonzalez JM, Anderson CAM, et al. Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association. Circulation 2021; 143:e902.</a></li><li><a class="nounderline abstract_t">Crump C, Sundquist J, McLaughlin MA, et al. Adverse pregnancy outcomes and long term risk of ischemic heart disease in mothers: national cohort and co-sibling study. BMJ 2023; 380:e072112.</a></li><li><a class="nounderline abstract_t">Parikh NI, Jeppson RP, Berger JS, et al. Reproductive Risk Factors and Coronary Heart Disease in the Women's Health Initiative Observational Study. Circulation 2016; 133:2149.</a></li><li><a class="nounderline abstract_t">Kharazmi E, Dossus L, Rohrmann S, Kaaks R. Pregnancy loss and risk of cardiovascular disease: a prospective population-based cohort study (EPIC-Heidelberg). Heart 2011; 97:49.</a></li><li><a class="nounderline abstract_t">Smith GC, Pell JP, Walsh D. Spontaneous loss of early pregnancy and risk of ischaemic heart disease in later life: retrospective cohort study. BMJ 2003; 326:423.</a></li><li><a class="nounderline abstract_t">Kharazmi E, Fallah M, Luoto R. Miscarriage and risk of cardiovascular disease. Acta Obstet Gynecol Scand 2010; 89:284.</a></li><li><a class="nounderline abstract_t">Ranthe MF, Andersen EA, Wohlfahrt J, et al. Pregnancy loss and later risk of atherosclerotic disease. Circulation 2013; 127:1775.</a></li><li><a class="nounderline abstract_t">Oliver-Williams CT, Heydon EE, Smith GC, Wood AM. Miscarriage and future maternal cardiovascular disease: a systematic review and meta-analysis. Heart 2013; 99:1636.</a></li><li><a class="nounderline abstract_t">Wagner MM, Bhattacharya S, Visser J, et al. Association between miscarriage and cardiovascular disease in a Scottish cohort. Heart 2015; 101:1954.</a></li><li><a class="nounderline abstract_t">Asgharvahedi F, Gholizadeh L, Siabani S. The risk of cardiovascular disease in women with a history of miscarriage and/or stillbirth. Health Care Women Int 2019; 40:1117.</a></li><li><a class="nounderline abstract_t">Grandi SM, Filion KB, Yoon S, et al. Cardiovascular Disease-Related Morbidity and Mortality in Women With a History of Pregnancy Complications. Circulation 2019; 139:1069.</a></li><li><a class="nounderline abstract_t">Peters SA, Woodward M. Women's reproductive factors and incident cardiovascular disease in the UK Biobank. Heart 2018; 104:1069.</a></li><li><a class="nounderline abstract_t">Canoy D, Beral V, Balkwill A, et al. Age at menarche and risks of coronary heart and other vascular diseases in a large UK cohort. Circulation 2015; 131:237.</a></li><li><a class="nounderline abstract_t">Charalampopoulos D, McLoughlin A, Elks CE, Ong KK. Age at menarche and risks of all-cause and cardiovascular death: a systematic review and meta-analysis. Am J Epidemiol 2014; 180:29.</a></li><li><a class="nounderline abstract_t">Lakshman R, Forouhi NG, Sharp SJ, et al. Early age at menarche associated with cardiovascular disease and mortality. J Clin Endocrinol Metab 2009; 94:4953.</a></li><li><a class="nounderline abstract_t">Mueller NT, Odegaard AO, Gross MD, et al. Age at menarche and cardiovascular disease mortality in Singaporean Chinese women: the Singapore Chinese Health Study. Ann Epidemiol 2012; 22:717.</a></li><li><a class="nounderline abstract_t">Lee JJ, Cook-Wiens G, Johnson BD, et al. Age at Menarche and Risk of Cardiovascular Disease Outcomes: Findings From the National Heart Lung and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation. J Am Heart Assoc 2019; 8:e012406.</a></li><li><a class="nounderline abstract_t">Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999; 159:1061.</a></li><li><a class="nounderline abstract_t">Mondul AM, Rodriguez C, Jacobs EJ, Calle EE. Age at natural menopause and cause-specific mortality. Am J Epidemiol 2005; 162:1089.</a></li><li><a class="nounderline abstract_t">Honigberg MC, Zekavat SM, Aragam K, et al. Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. JAMA 2019; 322:2411.</a></li><li><a class="nounderline abstract_t">Yuk JS, Kim BG, Lee BK, et al. Association of Early Hysterectomy With Risk of Cardiovascular Disease in Korean Women. JAMA Netw Open 2023; 6:e2317145.</a></li><li><a class="nounderline abstract_t">Ley SH, Li Y, Tobias DK, et al. Duration of Reproductive Life Span, Age at Menarche, and Age at Menopause Are Associated With Risk of Cardiovascular Disease in Women. J Am Heart Assoc 2017; 6.</a></li><li><a class="nounderline abstract_t">Amaya-Amaya J, Montoya-Sánchez L, Rojas-Villarraga A. Cardiovascular involvement in autoimmune diseases. Biomed Res Int 2014; 2014:367359.</a></li><li><a class="nounderline abstract_t">Gernaat SAM, Ho PJ, Rijnberg N, et al. Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat 2017; 164:537.</a></li><li><a class="nounderline abstract_t">Bradshaw PT, Stevens J, Khankari N, et al. Cardiovascular Disease Mortality Among Breast Cancer Survivors. Epidemiology 2016; 27:6.</a></li><li><a class="nounderline abstract_t">Kirkham AA, Beaudry RI, Paterson DI, et al. Curing breast cancer and killing the heart: A novel model to explain elevated cardiovascular disease and mortality risk among women with early stage breast cancer. Prog Cardiovasc Dis 2019; 62:116.</a></li><li><a class="nounderline abstract_t">Mehta LS, Watson KE, Barac A, et al. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation 2018; 137:e30.</a></li><li><a class="nounderline abstract_t">Jones LW, Haykowsky MJ, Swartz JJ, et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007; 50:1435.</a></li><li><a class="nounderline abstract_t">Masoudkabir F, Sarrafzadegan N, Gotay C, et al. Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis 2017; 263:343.</a></li><li><a class="nounderline abstract_t">Park NJ, Chang Y, Bender C, et al. Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women's Health Initiative. PLoS One 2017; 12:e0184174.</a></li><li><a class="nounderline abstract_t">Anderson C, Nichols HB, Deal AM, et al. Changes in cardiovascular disease risk and risk factors among women with and without breast cancer. Cancer 2018; 124:4512.</a></li><li><a class="nounderline abstract_t">Koene RJ, Prizment AE, Blaes A, Konety SH. Shared Risk Factors in Cardiovascular Disease and Cancer. Circulation 2016; 133:1104.</a></li><li><a class="nounderline abstract_t">Sabiston CM, Brunet J, Vallance JK, Meterissian S. Prospective examination of objectively assessed physical activity and sedentary time after breast cancer treatment: sitting on the crest of the teachable moment. Cancer Epidemiol Biomarkers Prev 2014; 23:1324.</a></li><li><a class="nounderline abstract_t">Irwin ML, Crumley D, McTiernan A, et al. Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer 2003; 97:1746.</a></li><li><a class="nounderline abstract_t">Kwan ML, Sternfeld B, Ergas IJ, et al. Change in physical activity during active treatment in a prospective study of breast cancer survivors. Breast Cancer Res Treat 2012; 131:679.</a></li><li><a class="nounderline abstract_t">Rock CL, Flatt SW, Newman V, et al. Factors associated with weight gain in women after diagnosis of breast cancer. Women's Healthy Eating and Living Study Group. J Am Diet Assoc 1999; 99:1212.</a></li><li><a class="nounderline abstract_t">Demark-Wahnefried W, Campbell KL, Hayes SC. Weight management and its role in breast cancer rehabilitation. Cancer 2012; 118:2277.</a></li><li><a class="nounderline abstract_t">Ekenga CC, Wang X, Pérez M, et al. A Prospective Study of Weight Gain in Women Diagnosed with Early-Stage Invasive Breast Cancer, Ductal Carcinoma In Situ, and Women Without Breast Cancer. J Womens Health (Larchmt) 2020; 29:524.</a></li><li><a class="nounderline abstract_t">Custódio ID, Marinho Eda C, Gontijo CA, et al. Impact of Chemotherapy on Diet and Nutritional Status of Women with Breast Cancer: A Prospective Study. PLoS One 2016; 11:e0157113.</a></li><li><a class="nounderline abstract_t">Kwok A, Palermo C, Boltong A. Dietary experiences and support needs of women who gain weight following chemotherapy for breast cancer. Support Care Cancer 2015; 23:1561.</a></li><li><a class="nounderline abstract_t">Malhotra A, Kort S, Lauther T, et al. Prevalence and Predictors of Cardiovascular Disease and Risk Factors in Transgender Persons in the United States. Crit Pathw Cardiol 2022; 21:42.</a></li><li><a class="nounderline abstract_t">Elamin MB, Garcia MZ, Murad MH, et al. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin Endocrinol (Oxf) 2010; 72:1.</a></li><li><a class="nounderline abstract_t">Asscheman H, Giltay EJ, Megens JA, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011; 164:635.</a></li><li><a class="nounderline abstract_t">Wierckx K, Elaut E, Declercq E, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol 2013; 169:471.</a></li><li><a class="nounderline abstract_t">Gooren LJ, Wierckx K, Giltay EJ. Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern. Eur J Endocrinol 2014; 170:809.</a></li><li><a class="nounderline abstract_t">Connelly PJ, Marie Freel E, Perry C, et al. Gender-Affirming Hormone Therapy, Vascular Health and Cardiovascular Disease in Transgender Adults. Hypertension 2019; 74:1266.</a></li><li><a class="nounderline abstract_t">Nota NM, Wiepjes CM, de Blok CJM, et al. Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy. Circulation 2019; 139:1461.</a></li><li><a class="nounderline abstract_t">Streed CG Jr, Harfouch O, Marvel F, et al. Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review. Ann Intern Med 2017; 167:256.</a></li><li><a class="nounderline abstract_t">Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, et al. Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2017; 102:3914.</a></li><li><a class="nounderline abstract_t">Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008; 93:19.</a></li><li><a class="nounderline abstract_t">Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132.</a></li><li class="breakAll">Feldman J. Preventive care of the transgender patient. In: Principles of Transgender Medicine and Surgery, Ettner R, Monstrey S, Coleman E (Eds), Routledge, 2016.</li></ol></div><div id="topicVersionRevision">Topic 1468 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32667846" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Feasibility and Utility of a Cardiovascular Risk Screening Tool in Women Undergoing Routine Gynecology Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28705320" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Quality and Equitable Health Care Gaps for Women: Attributions to Sex Differences in Cardiovascular Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27785341" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sex and gender medicine in physician clinical training: results of a large, single-center survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34010613" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34010613" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30803890" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Women-specific predictors of cardiovascular disease risk - new paradigms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30879355" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33779213" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36724989" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Adverse pregnancy outcomes and long term risk of ischemic heart disease in mothers: national cohort and co-sibling study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27143682" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Reproductive Risk Factors and Coronary Heart Disease in the Women's Health Initiative Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21123827" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pregnancy loss and risk of cardiovascular disease: a prospective population-based cohort study (EPIC-Heidelberg).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12595381" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Spontaneous loss of early pregnancy and risk of ischaemic heart disease in later life: retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19943820" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Miscarriage and risk of cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23536362" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pregnancy loss and later risk of atherosclerotic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23539554" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Miscarriage and future maternal cardiovascular disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26246401" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Association between miscarriage and cardiovascular disease in a Scottish cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30951435" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The risk of cardiovascular disease in women with a history of miscarriage and/or stillbirth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30779636" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cardiovascular Disease-Related Morbidity and Mortality in Women With a History of Pregnancy Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29335253" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Women's reproductive factors and incident cardiovascular disease in the UK Biobank.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25512444" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Age at menarche and risks of coronary heart and other vascular diseases in a large UK cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24920784" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Age at menarche and risks of all-cause and cardiovascular death: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19880785" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Early age at menarche associated with cardiovascular disease and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22939833" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Age at menarche and cardiovascular disease mortality in Singaporean Chinese women: the Singapore Chinese Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31165670" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Age at Menarche and Risk of Cardiovascular Disease Outcomes: Findings From the National Heart Lung and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10335682" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Age at natural menopause and risk of cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16221806" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Age at natural menopause and cause-specific mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31738818" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37307002" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Association of Early Hysterectomy With Risk of Cardiovascular Disease in Korean Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097389" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Duration of Reproductive Life Span, Age at Menarche, and Age at Menopause Are Associated With Risk of Cardiovascular Disease in Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25177690" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cardiovascular involvement in autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28503723" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Risk of death from cardiovascular disease following breast cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26414938" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cardiovascular Disease Mortality Among Breast Cancer Survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30797800" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Curing breast cancer and killing the heart: A novel model to explain elevated cardiovascular disease and mortality risk among women with early stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29437116" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919562" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Early breast cancer therapy and cardiovascular injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28624099" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28934233" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women's Health Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30291812" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Changes in cardiovascular disease risk and risk factors among women with and without breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26976915" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Shared Risk Factors in Cardiovascular Disease and Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24753546" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prospective examination of objectively assessed physical activity and sedentary time after breast cancer treatment: sitting on the crest of the teachable moment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12655532" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21953007" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Change in physical activity during active treatment in a prospective study of breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10524383" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Factors associated with weight gain in women after diagnosis of breast cancer. Women's Healthy Eating and Living Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22488702" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Weight management and its role in breast cancer rehabilitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31460829" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A Prospective Study of Weight Gain in Women Diagnosed with Early-Stage Invasive Breast Cancer, Ductal Carcinoma In Situ, and Women Without Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27310615" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Impact of Chemotherapy on Diet and Nutritional Status of Women with Breast Cancer: A Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25398359" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Dietary experiences and support needs of women who gain weight following chemotherapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34798650" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prevalence and Predictors of Cardiovascular Disease and Risk Factors in Transgender Persons in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19473174" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21266549" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23904280" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24616414" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31656099" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Gender-Affirming Hormone Therapy, Vascular Health and Cardiovascular Disease in Transgender Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30776252" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28738421" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28945852" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17986639" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19509099" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
